A Comparison of Two Standard Therapies in the Management of Dementia With Agitation

Completed · Phase 4

Conditions studied: Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease, Dementia

In brief

The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex is the most effective and safest way to treat agitation in elderly patients with dementia.

Key facts

Study ID

NCT00208819

Run by

Emory University

People needed

50

Starts

2003-09-01

Expected to finish

2007-07-01

Last updated by the study team

2013-11-13

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• inpatients admitted to Wesley Woods Inpatient service for Dementia with psychosis and agitation; taking risperidone (up to 1.5 mg/day), quetiapine (up to 175 mg/day), or olanzapine (up to 7.5 mg/day)

You may not qualify if…

• prior sensitivity to risperidone, quetiapine, olanzapine or divalproex

Where it is running

• Wesley Woods Geriatric Hospital — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.